This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Sanofi-A Ventis Deutschland Gmbh. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Claus-Jürgen Maier: Innovator in Chemical Synthesis
Introduction
Claus-Jürgen Maier is a notable inventor based in Hemsbach, Germany. He has made significant contributions to the field of chemical synthesis, particularly in the development of valuable intermediates for pharmaceutical applications. His work is characterized by a focus on innovative processes that enhance the efficiency of compound synthesis.
Latest Patents
One of Claus-Jürgen Maier's key patents is titled "Synthesis of 2-chloromethyl-6-methylbenzoic ester." This patent describes a process for preparing compounds of a specific formula, where R can be hydrogen or various substituted groups. The compounds produced through this process serve as valuable intermediates in the synthesis of PPAR agonists, which are important in medical research and drug development. He holds 1 patent in this area.
Career Highlights
Claus-Jürgen Maier is associated with Sanofi-Aventis Deutschland GmbH, a leading global pharmaceutical company. His role at the company has allowed him to work on innovative projects that contribute to advancements in the pharmaceutical industry. His expertise in chemical synthesis has positioned him as a valuable asset within his organization.
Collaborations
Throughout his career, Claus-Jürgen Maier has collaborated with several professionals in the field. Notable coworkers include Tobias Metzenthin and Joachim Graeser, who have worked alongside him on various projects. These collaborations have further enriched his contributions to chemical synthesis and innovation.
Conclusion
Claus-Jürgen Maier's work exemplifies the impact of innovation in the field of chemical synthesis. His patent contributions and collaborations highlight his commitment to advancing pharmaceutical research. His achievements continue to influence the development of important compounds in the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
